PerkinElmer, Inc. (NYSE: PKI), a world leader in Health Sciences and Photonics, today announced that it has secured the exclusive global rights to Placental Protein 13 (PP13), a new prospective biomarker for identifying patients at risk for preeclampsia developed by Diagnostic Technologies Ltd. (DTL), a developer of diagnostic kits and devices for monitoring pregnancies at risk.
